(BNTC) Benitec Biopharma - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US08205P2092
Stock: Gene Therapy, RNA Interference, BB-301, AAV Vector
Total Rating 17
Risk 30
Buy Signal -0.47
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.8% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.36 |
| Alpha | -9.46 |
| Character TTM | |
|---|---|
| Beta | 0.737 |
| Beta Downside | 0.434 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.93% |
| CAGR/Max DD | 0.56 |
Description: BNTC Benitec Biopharma December 28, 2025
Benitec Biopharma Ltd (NASDAQ:BNTC) is a clinical-stage biotech that has built a “Silence and Replace” platform, merging RNA interference with AAV-mediated gene therapy to both knock down pathogenic genes and deliver functional copies in a single dose. Its lead candidate, BB-301, targets the genetic cause of oculopharyngeal muscular dystrophy (OPMD)-related dysphagia by silencing the mutant gene and providing a wild-type replacement via an adeno-associated virus vector.
Key sector and company metrics to watch: (1) The global AAV-based gene-therapy market is projected to exceed $10 billion by 2030, driven by expanding FDA approvals and reimbursement pathways; (2) Benitec reported cash and equivalents of roughly $45 million at the end of Q2 2024, giving it an estimated 12-month runway at current burn rates; (3) R&D spending has risen ~30 % YoY, reflecting accelerated pre-clinical work on BB-301 and a parallel pipeline of rare-disease programs.
For a deeper, data-driven look at BNTC’s valuation dynamics, you might find ValueRay’s analytical dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -46.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 4.92 > 1.0 |
| NWC/Revenue: 16.7k% < 20% (prev 1.06m%; Δ -1.05m% < -1%) |
| CFO/TA -0.24 > 3% & CFO -22.7m > Net Income -46.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 46.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.5m) vs 12m ago 290.1% < -2% |
| Gross Margin: -15.74% > 18% (prev -44.50%; Δ 2876 % > 0.5%) |
| Asset Turnover: 0.67% > 50% (prev 0.01%; Δ 0.67% > 0%) |
| Interest Coverage Ratio: -29.78 > 6 (EBITDA TTM -48.9m / Interest Expense TTM 1.65m) |
Altman Z'' -15.00
| A: 0.97 (Total Current Assets 95.1m - Total Current Liabilities 2.02m) / Total Assets 96.0m |
| B: -2.47 (Retained Earnings -237.1m / Total Assets 96.0m) |
| C: -0.59 (EBIT TTM -49.0m / Avg Total Assets 82.4m) |
| D: -97.98 (Book Value of Equity -237.9m / Total Liabilities 2.43m) |
| Altman-Z'' Score: -108.6 = D |
Beneish M 1.00
| DSRI: 0.02 (Receivables 7000 /4000 , Revenue 556.0k/6000 ) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.66 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 92.67 (Revenue 556.0k / 6000 ) |
| TATA: -0.25 (NI -46.4m - CFO -22.7m) / TA 96.0m) |
| Beneish M-Score: 61.44 (Cap -4..+1) = D |
What is the price of BNTC shares?
As of February 07, 2026, the stock is trading at USD 12.12 with a total of 140,156 shares traded.
Over the past week, the price has changed by -0.49%, over one month by +1.08%, over three months by +1.00% and over the past year by +5.57%.
Over the past week, the price has changed by -0.49%, over one month by +1.08%, over three months by +1.00% and over the past year by +5.57%.
Is BNTC a buy, sell or hold?
Benitec Biopharma has received a consensus analysts rating of 4.57.
Therefore, it is recommended to buy BNTC.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BNTC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.8 | 96.6% |
| Analysts Target Price | 23.8 | 96.6% |
| ValueRay Target Price | 10.7 | -12% |
BNTC Fundamental Data Overview February 03, 2026
P/S = 2770.1307
P/B = 4.562
Revenue TTM = 556.0k USD
EBIT TTM = -49.0m USD
EBITDA TTM = -48.9m USD
Long Term Debt = 817.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 414.0k USD (from shortTermDebt, last quarter)
Debt = 817.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.7m USD (from netDebt column, last quarter)
Enterprise Value = 318.8m USD (412.4m + Debt 817.0k - CCE 94.5m)
Interest Coverage Ratio = -29.78 (Ebit TTM -49.0m / Interest Expense TTM 1.65m)
EV/FCF = -14.05x (Enterprise Value 318.8m / FCF TTM -22.7m)
FCF Yield = -7.12% (FCF TTM -22.7m / Enterprise Value 318.8m)
FCF Margin = -4080 % (FCF TTM -22.7m / Revenue TTM 556.0k)
Net Margin = -8349 % (Net Income TTM -46.4m / Revenue TTM 556.0k)
Gross Margin = -15.74% ((Revenue TTM 556.0k - Cost of Revenue TTM 643.5k) / Revenue TTM)
Gross Margin QoQ = none% (prev 50.0%)
Tobins Q-Ratio = 3.32 (Enterprise Value 318.8m / Total Assets 96.0m)
Interest Expense / Debt = 100.7% (Interest Expense 823.0k / Debt 817.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -38.7m (EBIT -49.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 46.95 (Total Current Assets 95.1m / Total Current Liabilities 2.02m)
Debt / Equity = 0.01 (Debt 817.0k / totalStockholderEquity, last quarter 93.6m)
Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -93.7m / EBITDA -48.9m)
Debt / FCF = 4.13 (negative FCF - burning cash) (Net Debt -93.7m / FCF TTM -22.7m)
Total Stockholder Equity = 91.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.34% (Net Income -46.4m / Total Assets 96.0m)
RoE = -50.96% (Net Income TTM -46.4m / Total Stockholder Equity 91.1m)
RoCE = -53.33% (EBIT -49.0m / Capital Employed (Equity 91.1m + L.T.Debt 817.0k))
RoIC = -42.51% (negative operating profit) (NOPAT -38.7m / Invested Capital 91.1m)
WACC = 8.61% (E(412.4m)/V(413.3m) * Re(8.63%) + (debt cost/tax rate unavailable))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 100.7%
Fair Price DCF = unknown (Cash Flow -22.7m)
EPS Correlation: 6.28 | EPS CAGR: 4.08% | SUE: 1.85 | # QB: 2
Revenue Correlation: 4.86 | Revenue CAGR: -62.47% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.24 | Chg30d=+0.002 | Revisions Net=+4 | Analysts=5
EPS current Year (2026-06-30): EPS=-1.04 | Chg30d=-0.032 | Revisions Net=+3 | Growth EPS=+0.9% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=-0.92 | Chg30d=+0.294 | Revisions Net=+1 | Growth EPS=+11.7% | Growth Revenue=+0.0%
P/B = 4.562
Revenue TTM = 556.0k USD
EBIT TTM = -49.0m USD
EBITDA TTM = -48.9m USD
Long Term Debt = 817.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 414.0k USD (from shortTermDebt, last quarter)
Debt = 817.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.7m USD (from netDebt column, last quarter)
Enterprise Value = 318.8m USD (412.4m + Debt 817.0k - CCE 94.5m)
Interest Coverage Ratio = -29.78 (Ebit TTM -49.0m / Interest Expense TTM 1.65m)
EV/FCF = -14.05x (Enterprise Value 318.8m / FCF TTM -22.7m)
FCF Yield = -7.12% (FCF TTM -22.7m / Enterprise Value 318.8m)
FCF Margin = -4080 % (FCF TTM -22.7m / Revenue TTM 556.0k)
Net Margin = -8349 % (Net Income TTM -46.4m / Revenue TTM 556.0k)
Gross Margin = -15.74% ((Revenue TTM 556.0k - Cost of Revenue TTM 643.5k) / Revenue TTM)
Gross Margin QoQ = none% (prev 50.0%)
Tobins Q-Ratio = 3.32 (Enterprise Value 318.8m / Total Assets 96.0m)
Interest Expense / Debt = 100.7% (Interest Expense 823.0k / Debt 817.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -38.7m (EBIT -49.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 46.95 (Total Current Assets 95.1m / Total Current Liabilities 2.02m)
Debt / Equity = 0.01 (Debt 817.0k / totalStockholderEquity, last quarter 93.6m)
Debt / EBITDA = 1.91 (negative EBITDA) (Net Debt -93.7m / EBITDA -48.9m)
Debt / FCF = 4.13 (negative FCF - burning cash) (Net Debt -93.7m / FCF TTM -22.7m)
Total Stockholder Equity = 91.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.34% (Net Income -46.4m / Total Assets 96.0m)
RoE = -50.96% (Net Income TTM -46.4m / Total Stockholder Equity 91.1m)
RoCE = -53.33% (EBIT -49.0m / Capital Employed (Equity 91.1m + L.T.Debt 817.0k))
RoIC = -42.51% (negative operating profit) (NOPAT -38.7m / Invested Capital 91.1m)
WACC = 8.61% (E(412.4m)/V(413.3m) * Re(8.63%) + (debt cost/tax rate unavailable))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 100.7%
Fair Price DCF = unknown (Cash Flow -22.7m)
EPS Correlation: 6.28 | EPS CAGR: 4.08% | SUE: 1.85 | # QB: 2
Revenue Correlation: 4.86 | Revenue CAGR: -62.47% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.24 | Chg30d=+0.002 | Revisions Net=+4 | Analysts=5
EPS current Year (2026-06-30): EPS=-1.04 | Chg30d=-0.032 | Revisions Net=+3 | Growth EPS=+0.9% | Growth Revenue=+0.0%
EPS next Year (2027-06-30): EPS=-0.92 | Chg30d=+0.294 | Revisions Net=+1 | Growth EPS=+11.7% | Growth Revenue=+0.0%